Deregulation of canonical oncogenic pathways such as E2F, K-RAS, p53, and Wnt/β-catenin signaling are known to occur with varying frequencies in GC [3]–[6], indicating that GC is a molecularly heterogeneous disease. The gene discussed is TP53; the disease is gastric cancer.